Perindopril: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Perindopril. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Cough | 12% |
| Back pain | 5.8% |
| Sinusitis | 5.2% |
| Viral infection | 3.4% |
| Upper extremity pain | 2.8% |
| Hypertonia | 2.7% |
| Dyspepsia | 1.9% |
| Fever | 1.5% |
| Proteinuria | 1.5% |
| Ear infection | 1.3% |
| Palpitation | 1.1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In…
Medical disclaimer: Always consult a qualified healthcare professional about any medication.